Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Béla Hunyady

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Orvosi Hetilap|May 14, 2011
[New therapeutic options in chronic hepatitis C virus infection]Béla Hunyady
Orvosi Hetilap|May 14, 2011
[Editor's commentary: 2011 Conference of the Hungarian Gastroenterology Society: Chronic viral hepatitis]Béla Hunyady, Alajos Pár
Orvosi Hetilap|December 4, 2004
[Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders]Beáta Gasztonyi, Béla Hunyady
Orvosi Hetilap|July 16, 2013
[Editor's commentary]Béla Hunyady, Ferenc Szalay
Orvosi Hetilap|June 4, 2015
[Financial burden of hepatitis C infection and its treatment]Mihály Makara, Béla Hunyady
Orvosi Hetilap|November 25, 2011
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]Béla Hunyady, Balázs Kovács, Zita Battyáni
Orvosi Hetilap|June 4, 2015
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals]Gábor Horváth, Tünde Halász, Mihály Makara, et al.
Orvosi Hetilap|January 18, 2006
[Safety of pegylated interferon in patients with hepatitis C virus induced cirrhosis]Beáta Gasztonyi, Gabriella Pár, Alajos Pár, et al.
Orvosi Hetilap|July 16, 2013
[Organizational characteristics of treatment for chronic hepatitis in Hungary: Hepatitis Registry and Priority Index]Mihály Makara, Gábor Horváth, Ferenc Szalay, et al.
Orvosi Hetilap|February 14, 2006
[The legal and occupational health aspects of B and C type viral hepatitis]Beáta Gasztonyi, Ildikó Antal, Erzsébet Szendy, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Orvosi Hetilap|May 14, 2011
[New therapeutic options in chronic hepatitis C virus infection]Béla Hunyady
Orvosi Hetilap|May 14, 2011
[Editor's commentary: 2011 Conference of the Hungarian Gastroenterology Society: Chronic viral hepatitis]Béla Hunyady, Alajos Pár
Orvosi Hetilap|December 4, 2004
[Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders]Beáta Gasztonyi, Béla Hunyady
Orvosi Hetilap|July 16, 2013
[Editor's commentary]Béla Hunyady, Ferenc Szalay
Orvosi Hetilap|June 4, 2015
[Financial burden of hepatitis C infection and its treatment]Mihály Makara, Béla Hunyady
Orvosi Hetilap|November 25, 2011
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]Béla Hunyady, Balázs Kovács, Zita Battyáni
Orvosi Hetilap|June 4, 2015
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals]Gábor Horváth, Tünde Halász, Mihály Makara, et al.
Orvosi Hetilap|January 18, 2006
[Safety of pegylated interferon in patients with hepatitis C virus induced cirrhosis]Beáta Gasztonyi, Gabriella Pár, Alajos Pár, et al.
Orvosi Hetilap|July 16, 2013
[Organizational characteristics of treatment for chronic hepatitis in Hungary: Hepatitis Registry and Priority Index]Mihály Makara, Gábor Horváth, Ferenc Szalay, et al.
Orvosi Hetilap|February 14, 2006
[The legal and occupational health aspects of B and C type viral hepatitis]Beáta Gasztonyi, Ildikó Antal, Erzsébet Szendy, et al.
Pageof 5